While a number of stocks have already seen a pullback on increasing risk this week, the sell-off should be limited for quality stocks in the long run. These include the mighty Enbridge, which, despite being one of the country’s widest economic moats, has weakened on news of the CER’s hold on its Mainline network.
The Big Five also offers discounted stocks right now. TD Bank, for instance, fell after news that its online brokerage arm, TD Ameritrade, had followed Charles Schwab into the zero-commission zone. TD stock was down 4.65% at the time of writing, while TD Ameritrade itself was down 27% on average for the week after the surprise announcement. Charles Schwabm, meanwhile, was down 15.25%.
Avoid falling knives and buy quality
Checking out the share price for Resverlogix for its five-day average on Monday morning, a would-be investor would have seen that the pharma stock had ditched 50%. However, checking back in midweek, the stock has bounced by 36%. This is extreme price volatility, and while it’s attracting the attention of momentum investors, it’s not a low-risk, long-range play in the pharma sector.
An alternative for a weakened stock in the specialty pharma space might be HEXO (TSX:HEXO)(NYSE:HEXO). The cannabis stock has pulled back after the company lost its CFO — the second key management figure to leave the company this year. Down 4% at the time of writing, HEXO could be a buy for patient cannabis investors who have been eyeing the stock for a dip.
While the next round of legalization will introduce a whole range of investment ideas, the window for upside could be closing. Indeed, with the vaping controversy weighing on Cannabis 2.0, it might even be better to sidestep the new marijuana asset classes and stick with stable growth. HEXO’s stakes in the CBD and medical marijuana markets could make for a tasty investment once its share price bottoms out.
A downturn would offer increasing value opportunities
If the markets decline and a bear market finally emerges, it may be time for low-risk contrarians to start using a dollar-cost strategy, pumping a set amount into the market each month no matter how dire the headlines. While cannabis may be too risky an area for such an investment plan, big names trading at deep discounts remain strong options.
Doubling down on wide-moat market leaders such as Enbridge during that kind of economic environment would be a strong long-term play, which would pay off once the markets rebound again. Low-risk investors should therefore start identifying defensive stocks such as key utilities, healthcare, and infrastructure assets with attractive fundamentals and draw up a bear market wish list ahead of time.
The bottom line
Building up a war chest during tough times is a strong move for long-term capital appreciation. It also keeps the markets stimulated, and can add passive income through dividends, allaying some of the financial worries that a downturn brings. Sticking with market leaders in classically defensive sectors reduces risk and goes some way to assuring income in a bear market.
- TFSA Investors: $63,500 in this Dividend Stock Pays $4,000 a Year
- BlackBerry (TSX:BB) Stock Is a Huge Buy
- Pension Wealth: How to Use the TFSA to Turn $10,000 Into $107,000 in Retirement Savings
- 3 Reasons Why Aurora Cannabis (TSX:ACB) Stock Is a Steal at $5
- Top stocks for 2019
- Two New Stock Picks Every Month!
Fool contributor Victoria Hetherington has no position in any of the stocks mentioned. The Motley Fool owns shares of Enbridge. Enbridge is a recommendation of Stock Advisor Canada.
The Motley Fool’s purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool Canada’s free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. Motley Fool Canada 2019